ChromaDex forms China JV for Tru Niagen, sells $3.1M stock to insiders at $1.25/sh

Niagen Bioscience, Inc.

Taikuk invests $1M for 11% non-voting stake in JV to commercialize Tru Niagen in China; Blue Hat registration required within 24 months.
Prior Term Sheet with Crystal Lake and Pioneer Idea terminated; new structure approved by Audit Committee.
Company sells 2.48M shares at $1.25 for $3.1M to existing holders including CEO Robert Fried; closing expected Oct 7, 2022.
Shares unregistered, sold under Rule 506; Registration Rights Agreement provides for future resale registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.